Mass spectrometry-based metabolomic and lipidomic profiling stratifies stages of diabetic retinopathy
- 22 August 2025
- journal article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 228, 112423
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82101141, 82171071)
This publication has 51 references indexed in Scilit:
- The association between plasma lipidome and diabetic microangiopathy: a mendelian randomization studyActa Diabetologica, 2024
- Targeting BCAA metabolism to potentiate metformin’s therapeutic efficacy in the treatment of diabetes in miceDiabetologia, 2023
- Mass spectrometry‐based extracellular vesicle micromolecule detection in cancer biomarker discovery: An overview of metabolomics and lipidomicsView, 2023
- SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db miceBiomedicine & Pharmacotherapy, 2022
- Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic RetinopathyJAMA Ophthalmology, 2021
- Serum sphingomyelin species profile is altered in hematologic malignanciesClinica Chimica Acta, 2021
- WGCNA Application to Proteomic and Metabolomic Data Analysis2017
- β-Hydroxy-β-methylbutyrate (HMB) prevents dexamethasone-induced myotube atrophyBiochemical and Biophysical Research Communications, 2012
- Specific, rapid, and sensitive enzymatic measurement of sphingomyelin, phosphatidylcholine and lysophosphatidylcholine in serum and lipid extractsClinical Biochemistry, 2008
- Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategyDiabetologia, 2008